Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.02/23/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 23, 2014 Category: Cancer & Oncology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers. (Source: MedWire News - Urology)
Source: MedWire News - Urology - February 21, 2014 Category: Urology & Nephrology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 21, 2014 Category: Cancer & Oncology Source Type: news

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies
To compare outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus, temsirolimus, and sorafenib following initial treatment with a tyrosine kinase inhibitor (TKI) in community and academic practices throughout the US.02/20/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 20, 2014 Category: Cancer & Oncology Source Type: news

Clin Onc News Report: Options in Multiple Myeloma, Renal Cell Carcinoma
(MedPage Today) -- A regular update on what's new in cancer research from our friends at Clinical Oncology News. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 18, 2014 Category: Hematology Source Type: news

Sunitinib safe, effective in patients with mRCC, renal insufficiency
Sunitinib demonstrated encouraging activity and manageable toxicities in patients with metastatic renal cell carcinoma and renal insufficiency, according to study results.02/14/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 14, 2014 Category: Cancer & Oncology Source Type: news

Vitreous Hemorrhage as the Initial Sign of Renal Cell Carcinoma Metastasis
Choroidal metastases generally appear as a solitary, yellow- or orange-colored mass in the macula or perimacular region of the eye. In an analysis of 520 eyes with uveal metastasis, the tumor appeared as a solitary mass (71%) with mean basal dimension of 9 mm and mean thickness of 3 mm.1 In that analysis, associated findings included subretinal fluid (73%) and retinal pigment epithelial alterations (57%). Hemorrhage is an unusual finding with choroidal metastatic disease. Single case reports have highlighted this rare association.02/11/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 11, 2014 Category: Cancer & Oncology Source Type: news

Survival Outcomes Similar Regardless of Sorafenib-Sunitinib Sequence in mRCC
The SWITCH trial makes it official: it makes no difference whether patients with metastatic renal cell carcinoma (mRCC) first start on sorafenib and then switch to sunitinib upon progression or vice versa.02/10/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 10, 2014 Category: Cancer & Oncology Source Type: news

Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management
Purpose Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary. No guidelines exist for patient selection for RCC germline mutation testing. We evaluate how age of onset could indicate the need for germline mutation testing for detection of inherited forms of kidney cancer.02/09/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 9, 2014 Category: Cancer & Oncology Source Type: news

Journal of the National Cancer Institute: Investigation of the Obesity Paradox in RCC
Obesity increases risk for clear-cell renal cell carcinoma, but obese patients appear to experience longer survival than nonobese patients. Why the paradox?02/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 7, 2014 Category: Cancer & Oncology Source Type: news

A Road Map for Success in RCC
SAN FRANCISCO (MedPage Today) -- Renal cell carcinoma had a mix of highs and lows over the past decade, and shifting the balance to the high side requires more emphasis on molecular biology and genetics, a clinician and investigator said here. (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - February 5, 2014 Category: Surgery Source Type: news

Two Strategies Lead to Similar Survival in RCC
SAN FRANCISCO (MedPage Today) -- Sequential targeted therapy for metastatic renal cell carcinoma led to similar survival, regardless of which agent was used first, according to the first randomized study of the issue. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - February 3, 2014 Category: Urology & Nephrology Source Type: news

MET variant as a prognostic marker in clear cell renal cell carcinoma
Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA02/02/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 2, 2014 Category: Cancer & Oncology Source Type: news

Results of the MARS study in renal cell carcinoma
Dr Vincent Launay-Vacher - Pitie-Salpetriere Hospital, Paris, France02/02/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 2, 2014 Category: Cancer & Oncology Source Type: news

2014 ASCO GU Renal Cell Cancer Abstracts
Meeting abstracts--search free!01/31/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 31, 2014 Category: Cancer & Oncology Source Type: news

Randomized Controlled Trial of Expressive Writing for Patients With Renal Cell Carcinoma
This randomized controlled trial examined the quality-of-life benefits of an expressive writing (EW) intervention for patients with renal cell carcinoma (RCC) and identified a potential underlying mechanism of intervention efficacy.01/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2014 Category: Cancer & Oncology Source Type: news

Argos Therapeutics To Present Progress Update On Adapt Phase 3 Trial With AGS-003 At 2014 Genitourinary Cancers Symposium
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company will present a trial-in-progress update on the company's ongoing pivotal phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC).01/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2014 Category: Cancer & Oncology Source Type: news

FDG-PET as a predictive biomarker
The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression.01/28/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 28, 2014 Category: Cancer & Oncology Source Type: news

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
DNA aptamers represent a novel strategy in anti-cancer medicine.01/22/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 22, 2014 Category: Cancer & Oncology Source Type: news

Biomarkers of renal cell carcinoma
The incidence of renal cell carcinoma (RCC) has increased steadily in past few decades and is partially attributable to the increased utilization of cross-sectional imaging.01/21/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 21, 2014 Category: Cancer & Oncology Source Type: news

Kidney cancer before age 47 implies hereditary cause
The diagnosis of renal cell cancer in a patient aged 46 or younger should prompt a referral for germline mutation testing and genetic counseling, according to a report published online in the Journal of Clinical Oncology.01/19/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 19, 2014 Category: Cancer & Oncology Source Type: news

Pathological characteristics and prognostic effect of peritumoral capsule penetration in renal cell carcinoma after tumor enucleation
To evaluate the pathological characteristics of peritumoral capsule (PC) and the prognostic effect of capsule penetration on tumor recurrence in patients treated with tumor enucleation for clinically intracapsular renal cell carcinomas (RCCs).01/18/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 18, 2014 Category: Cancer & Oncology Source Type: news

Obesity associated with tumor indolence in renal cell carcinoma
Obese patients with renal cell carcinoma tended to have more indolent tumors than normal-weight patients, according to study results.01/17/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 17, 2014 Category: Cancer & Oncology Source Type: news

Rexahn begins Phase IIa trial of renal carcinoma drug Archexin
US-based clinical stage biopharmaceutical firm Rexahn Pharmaceuticals has started a multi-centre Phase IIa clinical proof-of-concept trial to evaluate the safety and efficacy of Archexin in patients with metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - January 16, 2014 Category: Pharmaceuticals Source Type: news

Patient Resource Cancer Guide: Renal Cell Carcinoma
Click to download and read the PDF now: Prefer to have it in print?  Click here to order online.01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Cancer & Oncology Source Type: news

Patient Resource Cancer Guide: Renal Cell Carcinoma
Click to download and read the PDF now: Prefer to have it in print?  Click here to order online.01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Urology & Nephrology Source Type: news

Patient Resource Cancer Guide: Renal Cell Carcinoma
Click to download and read the PDF now: Prefer to have it in print? Click here to order online.01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Urology & Nephrology Source Type: news

Rexahn Initiates Phase IIa Clinical Trial of Archexin® in Patients with Metastatic Renal Cell Carcinoma
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin® in patients with metastatic renal cell carcinoma (RCC). Archexin was previously granted Orphan Drug Designation for the RCC indication.01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Cancer & Oncology Source Type: news

Rexahn Initiates Phase IIa Clinical Trial of Archexin ® in Patients with Metastatic Renal Cell Carcinoma
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin ® in patients with metastatic renal cell carcinoma (RCC). Archexin was previously granted Orphan Drug Designation for the RCC indication. 01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Urology & Nephrology Source Type: news

Rexahn initiates Phase Ib clinical trial of RX-3117 for treatment of solid tumors
RX-3117 has broad spectrum anti-tumor activity against 80 different human cancer cell lines (including NSCLC, breast, ovarian, pancreas, colon, renal, brain, bladder, cervical) and efficacy in 12 different mouse xenograft models (including colorectal, non-small cell lung, pancreatic and renal cell carcinoma) superior to that of gemcitabine.01/10/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 10, 2014 Category: Cancer & Oncology Source Type: news

Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma
Renal cell carcinoma (RCC) frequently metastasizes to the spine, and the prognosis can be quite variable.01/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 7, 2014 Category: Cancer & Oncology Source Type: news

NewLink Genetics initiates Phase I renal cell cancer trial
NewLink Genetics Corporation, a biopharmaceutical company, has initiated a first in human Phase I clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer.01/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 7, 2014 Category: Cancer & Oncology Source Type: news

Newlink genetics launches phase i clinical trial
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer.12/20/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 20, 2013 Category: Cancer & Oncology Source Type: news

Merck, Glaxo to Partner on Renal Cell Cancer Treatment
Merck is looking for more collaborations like the one with Glaxo to test how MK-3475 works with other anticancer treatments against a variety of tumor types...12/19/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 19, 2013 Category: Cancer & Oncology Source Type: news

Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7...
Source: Merck.com - Research and Development News - December 18, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Chromophobe renal cell carcinoma with concomitant sarcomatoid transformation
Chromophobe renal cell carcinoma is the third most common form of adult renal epithelial neoplasm. A sarcomatoid component occurs in approximately 8% of all chromophobe renal cell carcinoma cases, while metaplastic bone formation is extremely rare.12/14/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2013 Category: Cancer & Oncology Source Type: news

Findings on Carcinomas Reported by Investigators at University of Texas
"We prospectively assessed the efficacy and safety of axitinib dose titration in previously untreated patients with metastatic renal-cell carcinoma. In this randomised, double-blind, multicentre, phase 2 study, patients were enrolled from 49 hospitals and outpatient clinics in the Czech Republic, Germany, Japan, Russia, Spain, and USA. Patients with treatment-naive metastatic renal-cell carcinoma received axitinib 5 mg twice daily during a 4 week lead-in period..."12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

First-Line Inlyta Active in Metastatic Kidney Cancer
First-line therapy with Inlyta® (axitinib) demonstrated clinical activity in metastatic renal cell carcinoma, according to the results of a study published in The Lancet Oncology.12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

Low sodium levels linked to poor targeted therapy outcomes
Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate.12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

Early tumor shrinkage predicts targeted therapy efficacy
Early tumor shrinkage in patients with metastatic renal cell carcinoma (mRCC) following vascular endothelial growth factor (VEGF)-targeted therapy may herald good long-term survival, research shows.12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

Predicting outcome for high-dose IL-2 therapy
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission;..12/11/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 11, 2013 Category: Cancer & Oncology Source Type: news

Renal Cell Carcinoma Development and miRNAsRenal Cell Carcinoma Development and miRNAs
The majority of renal cell carcinoma cases are detected accidentally, and often at a late stage. Could miRNAS serve as potential biomarkers for diagnosis and prognosis? Pharmacogenomics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Early tumor shrinkage predicts targeted therapy efficacy in RCC
Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news

Low sodium levels linked to poor targeted therapy outcomes in RCC
Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news

Clinical heterogeneity of Xp11 translocation renal cell carcinoma
Impact of fusion subtype, age, and stage12/09/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 8, 2013 Category: Cancer & Oncology Source Type: news

Cystic partially regressed clear cell renal cell carcinoma
A potential mimic of multilocular cystic renal cell carcinoma12/07/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 7, 2013 Category: Cancer & Oncology Source Type: news

Targeted Tx Fails 2 Tests in Metastatic Renal Cancer
(MedPage Today) -- A mammalian target of rapamycin (mTOR) inhibitor failed to improve outcomes in metastatic renal cell carcinoma (RCC) as compared with other therapeutic options, according to two randomized trials. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 4, 2013 Category: Urology & Nephrology Source Type: news

Predicting outcome for cancer patients receiving high-dose IL-2 therapy
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment. Because HD IL-2-associated toxicity is severe, it would be beneficial for clinicians to determine if a patient would respond favorably to this treatment prior to side effect onset. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 3, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

VEGF Receptor Tyrosine Kinase Inhibitors in Metastatic RCCVEGF Receptor Tyrosine Kinase Inhibitors in Metastatic RCC
Recent metastatic renal cell carcinoma clinical trial results have implications for management of patients. Find out more. Therapeutic Advances in Medical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases
OBJECTIVE: To investigate the prognosis and prognostic factors of patients with metastatic renal cell carcinoma who underwent metastasectomy.11/29/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 29, 2013 Category: Cancer & Oncology Source Type: news